Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Medical cannabis

Government drugs advisory body to review impact of medical cannabis reschedule

The Advisory Council for the Misuse of Drugs (ACMD) has been asked by the Home Office to begin a long-term review into cannabis-based products for medical use.

The review will assess the impact of medical cannabis being moved from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations (MDR) 2001, and will also look at whether any further legislative amendments are needed.

In July 2018, the ACMD completed a short-term review of cannabis-derived medical products, which concluded that these products should be rescheduled because there was “evidence of medicinal benefit for some cannabis-derived products in certain medical conditions for some patients”. The legislative change came into force on 1 November 2018.

The short-term review recommended that synthetic cannabinoids remain in Schedule 1; because of the “associated potency and harms” associated with the use of some of these products — which include the street drugs ‘spice’ and ‘mamba’ — the ACMD concluded that it needed “further time to consider and consult on the unintended consequences of potential rescheduling”. The longer-term review will include an updated harms assessment and a consideration of whether synthetic cannabinoids should now be rescheduled.

The council has been asked to complete the review by November 2020.

In January 2019, three members of the Royal Pharmaceutical Society were appointed to the ACMD. Carole Hunter, Roger Knaggs and David Taylor will hold their posts for three years.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206180

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.